Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: mutations present in more than 90% of cases. Daraxonrasib is an oral RAS(ON) multiselective, tri-complex inhibitor of the active guanosine triphosphate-bound state of mutant and wild-type RAS. METHODS: G12 and overall populations. Safety was also assessed. RESULTS: G12 population was 7.3 months with daraxonrasib and 3.5 months with chemotherapy, and that in the overall population was 7.2 months and 3.6 months, respectively; the hazard ratios were 0.45 and 0.49, respectively (P<0.001 for both comparisons). Adverse events that occurred after the start of treatment were reported in all the patients in the daraxonrasib group and in 97.7% of those in the chemotherapy group; the incidence of adverse events of grade 3 or higher was 61.8% and 69.6%, respectively. Treatment-related adverse events that led to treatment discontinuation occurred in 1.2% of the patients in the daraxonrasib group and in 11.2% of those in the chemotherapy group. CONCLUSIONS: Among patients with previously treated mPDAC, treatment with daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. (Funded by Revolution Medicines; RASolute 302 ClinicalTrials.gov number, NCT06625320.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In this trial, daraxonrasib significantly improved overall survival and progression-free survival compared with chemotherapy.”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [59]
In the citing paper
“In the overall population, median overall survival was 13.2 months with daraxonrasib versus 6.7 months with chemotherapy, and median progression-free survival was 7.2 versus 3.6 months, respectively.”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [59]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Integrated genomic characterization of pancreatic ductal adenocarcinoma
Raphael, B. J., Hruban, R. H., Aguirre, A. J., Moffitt, R. A., Yeh, J. J., Stewart, C., Robertson, A. G., Cherniack, A. D., Gupta, M., Getz, G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.007 · Cited by 2,019
Park, W., Chawla, A., & O’Reilly, E. M. (2021) · JAMA · doi:10.1001/jama.2021.13027 · Cited by 1,882
Self-citationPancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Conroy, T., Pfeiffer, P., Vilgrain, V., Lamarca, A., Seufferlein, T., O’Reilly, E. M., Hackert, T., Golan, T., Prager, G., Haustermans, K., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.08.009 · Cited by 610
Self-citationWainberg, Z. A., Melisi, D., Macarulla, T., Pazo Cid, R., Chandana, S. R., De La Fouchardière, C., Dean, A., Kiss, I., Lee, W. J., Goetze, T. O., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01366-1 · Cited by 516
Self-citationMultidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma
Grossberg, A. J., Chu, L. C., Deig, C. R., Fishman, E. K., Hwang, W. L., Maitra, A., Marks, D. L., Mehta, A., Nabavizadeh, N., Simeone, D. M., et al. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21626 · Cited by 489
Therapeutic developments in pancreatic cancer
Hu, Z. I., & O’Reilly, E. M. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00840-w · Cited by 413
Self-citation
Research works printed but not linked: 1
- Siegel RL, Kratzer TB, Wagle NS, Sung H, Jemal A. Cancer statistics, 2026. CA Cancer J Clin 2026;76(1):e70043-e70043.41528114
Cited by
Aronchik, I., Kar, S., Zhuang, Y., Ahler, E., Lai, L., Seshadri, V., Yang, Y. C., Bulle, A. S., Ménard, M., Nayak, B., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04537-w · Cited by 32
Self-citationMolecular dynamics driving phenotypic divergence among KRAS mutants in pancreatic tumorigenesis
Grimont, A., Falvo, D. J., Sisso, W. J., dos Santos, F., Chan, C. W., Zumbo, P., Fall, W. B., Ferrick, K. R., Pan, G., Cleveland, M., et al. (2026) · Developmental Cell · doi:10.1016/j.devcel.2026.06.016 · Cited by 5
Rosas, D., Barad, P., Wright, J., & Raez, L. E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146455 · Cited by 5
Dorbin, D., Herrera, J., Davidson, R., Chandrashekar, N., Scheuber, G., Jayakrishnan, P., Rajesh, C., Johnson, G., Yuan, J., Sochor, M., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-26-1181 · Cited by 5
Radiation Therapy for Pancreatic Cancer: An ASTRO Clinical Practice Guideline
Chuong, M. D., Jethwa, K. R., Ludmir, E., Narang, A., Reyngold, M., Anne, P. R., Bassetti, M., Brunner, T., Du, K. L., Frakes, J., et al. (2026) · Practical Radiation Oncology · doi:10.1016/j.prro.2026.07.002 · Cited by 4
Precision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond
Schürmann, H., Park, W., O'Kane, G. M., Sciortino, C., Niger, M., Reichert, M., Olive, K. P., Pretzell, I., & Westphalen, C. B. (2026) · Targeted Oncology · doi:10.1007/s11523-026-01236-x · Cited by 3
Conroy, T., & Ducreux, M. P. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.08.003 · Cited by 3
Ai, X., Song, Z., Wu, L., Zhou, A., Cheng, D., Zong, H., Wu, H., Niu, Z., Sun, Y., Zhu, L., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04559-4 · Cited by 3
Precision Oncology in Hepatopancreatobiliary Cancer Surgery
Newhook, T. E., Tsai, S., & Meric‐Bernstam, F. (2026) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2026.05.026 · Cited by 3
Daraxonrasib: A Breakthrough in Pancreatic Ductal Adenocarcinoma
Zacharia, G. S., Pandey, U., Thartori, O., Veena, F., Acharya, S., Shah, L. K., Patel, R., & Patel, H. (2026) · Cureus · doi:10.7759/cureus.113927 · Cited by 2
Self-citationİyikesici, M. S., Oncul, O., Hallaç, M., Şen, S., Taflan, Ş., Öncül, S., Duraj, T., & Seyfried, T. N. (2026) · Current Oncology · doi:10.3390/curroncol33080489 · Cited by 2
Dempke, W. C. M., Sippel, C., Fenchel, K., Heinemann, V., Cutsem, E. V., & Arnold, D. (2026) · Future Oncology · doi:10.1080/14796694.2026.2725499 · Cited by 2
Shi, S., Wei, M., Du, N., Li, J., Han, B., Wang, W., Hu, X., Luo, F., Xu, J., & Yu, X. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.08.012 · Cited by 2
Lou, J., & Zhang, D. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00833-w · Cited by 2
Pancreatic Adenocarcinoma, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology
Ko, A. H., Malafa, M. P., Aguilera, T., Basturk, O., Benson, A. B., Cardin, D. B., Chiorean, E. G., Christensen, J. A., Chung, V., Czito, B., et al. (2026) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2026.0046 · Cited by 2
Self-citationMevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-Resistant Pancreatic Cancer
Michels, A. K., Calderon, S. E., Nghiem, E., Zimmer, E., Santana, L. S., Singh, R., Eiseler, T., Allgöwer, C., Tong, G., Wu, S., et al. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.09.027 · Cited by 2
Pancreatic cancer: New drug results prompt standing ovation at oncology conference
Thornton, J. (2026) · BMJ · doi:10.1136/bmj-2026-902114 · Cited by 2
Ching, Y. M., Narayanan, S., Klomp, J. A., Isermann, T., Loewe, S., Chang, W.-H., Waters, A. M., Peña, S. R. N., Baldelli, E., Martin, C. P., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.10.743026 · Cited by 2
Tsai, A. K., Rollins, M. R., Ellefson, M. A., Schmiechen, Z. C., Burrack, A. L., Hulbert, A., Qian, G., Zhang, H., Cruz-Hinojoza, E., Butler, J. Z., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1101/2025.06.04.657887 · Cited by 1
Daraxonrasib (RMC-6236) is an effective targeted therapy for RAS-mutant neuroblastoma
Hill, R. D., Dalton, K. M., Kurupi, R., Xing, Y., Slaughter, J. M., Roberts, J., Kehinde, V. A., Zhang, K., Hu, B., Wang, L., et al. (2026) · Molecular Cancer Therapeutics · doi:10.64898/2026.02.19.706849 · Cited by 1
RAS Inhibitors: Changing the Paradigm from the Undruggable
Campana, F., Bellis, E. D., Porcaro, F., Guida, G. D., Gravara, L. D., Servetto, A., Morgillo, F., Papaccio, F., Filippelli, A., Corte, C. M. D., et al. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18070773 · Cited by 1
Actualités dans le traitement médical des adénocarcinomes pancréatiques
Rémond, M., & Coriat, R. (2026) · La Presse Médicale Formation · doi:10.1016/j.lpmfor.2026.100825 · Cited by 1
Prise en charge médicale de l’adénocarcinome du pancréas métastatique
Pellat, A., Lellouche, L., & Coriat, R. (2026) · La Presse Médicale Formation · doi:10.1016/j.lpmfor.2026.100824 · Cited by 1
RAS signaling at the crossroads of radioresistance and tumor immunity
Quevrin, C., Mondini, M., Meziani, L., de Thoré, M. G., Liu, W., Lopes, E., Morel, D., Clémenson, C., Deutsch, É., & Lévy, A. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2026-015274 · Cited by 1
Targeted Therapy in Pancreatic Ductal Adenocarcinoma: Current Advances and Challenges
Habib, R., Arnold, E., Obi, T., Vizeacoumar, F. J., & Ahmed, S. (2026) · Current Oncology · doi:10.3390/curroncol33080452 · Cited by 1
Salih, R., Sirajudeen, F., & Rahmani, M. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.08.030 · Cited by 1
Luchini, C. (2026) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-026-04681-1 · Cited by 1
KRAS-driven cytokine–metabolic crosstalk shapes immune exclusion in pancreatic ductal adenocarcinoma
Huang, C., Mai, G., Li, Y., Liu, H., & Huang, W. (2026) · Frontiers in Genetics · doi:10.3389/fgene.2026.1899014 · Cited by 1
Mariano, M. P., Sgarilli, E., Mijnlieff, D., Visuvasam, B., Blesio, A., Digiacomo, G., Cavazzoni, A., Ferracin, M., & Giovannetti, E. (2026) · Cancer Drug Resistance · doi:10.20517/cdr.2026.52 · Cited by 1
Mechanisms of Immune Cell Dysregulation in Pancreatic Ductal Adenocarcinoma
Ahmady, F., Luwor, R. B., & Kannourakis, G. (2026) · Biology · doi:10.3390/biology15181599 · Cited by 1
Li, Q., Hoffman, M. T., Chun, J.-H., Parent, B. D., Hambitzer, F., Peprah, F., Kureshi, C. T. S., Lim, B. S., Chang, E., Walsh, M. J., et al. (2026) · Cell · doi:10.1016/j.cell.2026.08.045 · Cited by 1
Self-citationDaraxonrasib: How soon could the new drug for pancreatic cancer be available in the UK?
Lang, K. (2026) · BMJ · doi:10.1136/bmj-2026-100870 · Cited by 1
Positive selection screen identifies natural product β-catenin inactivators
Boudreau, M. W., Freire, V. F., Corbett, S. C., Martínez-Fructuoso, L., Shenoy, S. R., Yu, W., Kumar, R., Thornburg, C. C., Akee, R. K., Peyser, B. D., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2625189123 · Cited by 1
Pancreatic Cancer KRAS Breakthrough: Drug Graveyard No More
Yu, P. Y., Oberstein, P. E., Maitra, A., & Hidalgo, M. M. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-4177 · Cited by 1
Self-citationKRAS Mutations in Cancers: From Undruggable Dilemma to Precision Medicine
Cai, J., Wu, Y., Jia, X., Yang, L., Yang, W., Lu, W., Huang, Z., Pan, Y., Fei, Z., Ru, J., et al. (2026) · MedComm · doi:10.1002/mco2.71050 · Cited by 1
Targeting RAS in pancreatic cancer
Petrelli, F., Dottorini, L., & Zaniboni, A. (2026) · Cancer · doi:10.1002/cncr.70640 · Cited by 1
Al-Koussa, H., Taniguchi, D., Kuroda, M., Inomata, Y., Huaze, Y., Machinaga, A., Kakiuchi, N., Ogawa, S., Seno, H., Higashiyama, S., et al. (2026) · Journal of Cell Science · doi:10.1242/jcs.265075 · Cited by 1
George, B., Singh, H., Devoe, C., Chung, V. M., Hosein, P. J., Hendifar, A., Kim, D. W., Valerin, J. B., Bekaii‐Saab, T., Cardin, D. B., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04734-7 · Cited by 1
Self-citationDaraxonrasib: a milestone for patients and European medicines regulation
Péan, E., Mengel, M. A., Josephson, F., Zondag, D. N., Sepodes, B. M. N., & Day, F. (2026) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2026.101914 · Cited by 1
Lieu, C. (2026) · The Conversation · doi:10.64628/aai.yr459rqxr · Cited by 1
Oncology must confront hidden side effects
(2026) · Nature Medicine · doi:10.1038/s41591-026-04554-9 · Cited by 1
Wang, T., Wang, L., Xu, J., Guo, Y., Xia, L., Li, Y., Guan, F., Gan, B., Hong, D. S., Bernard, V., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.10.737883 · Cited by 1
Breaking the RAS Barrier in Pancreatic Cancer
Sivakumar, S. (2026) · New England Journal of Medicine · doi:10.1056/nejme2606948 · Cited by 1
Daraxonrasib in Pancreatic Cancer: From Second-Line Breakthrough to First-Line Evidence
Ranganathan, S., & Olivier, T. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-01457 · Cited by 1
Single-cell perturbation prediction near experimental reproducibility with GENESISPreprint
Conci, R., D’Ascenzo, D., di Montesano, S. C., Raghavan, S., Winter, P. S., Allen, E. M. V., Crawford, L. A., & Lotter, W. E. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.30.763081 · Cited by 1
Kano, Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135796
the Thergap-2 Investigator Group, Louis, B., Marine, L., Naima, H., Sophie, G., Noémie, D., Fabienne, V., Gilles, C., Gross, F., Rosine, G., et al. (2026) · Cancer Drug Resistance · doi:10.20517/cdr.2026.68
Lieu, C. (2026) · The Conversation · doi:10.64628/aak.r3q3w57pn
Positive results for daraxonrasib for previously treated metastatic pancreatic cancer
Ray, K. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01222-8
Daraxonrasib effective in metastatic pancreatic ductal adenocarcinoma
Sidaway, P. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01176-5
ASCO 2026 Highlights for Surgical Oncologists: From Scalpel to Biology-Driven Strategy
Garg, P. K., Kaul, P., Kapur, K., Kumar, R., Poonia, D. R., Jakhetiya, A., & Somashekhar, S. P. (2026) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-026-02648-x
Cracking the “undruggable”: Landmark trial sparks hope for fighting “King of Cancers”
The Innovation Oncology News Team (2026) · The Innovation Oncology · doi:10.59717/j.xinn-oncol.2026.100018
M1C IS NECESSARY FOR DARAXONRASIB RESISTANCE OF NSCLC KRAS(G12C) MUTANT CELLSPreprint
Takamori, S., Haratake, N., Nonaka, K., Moriya, M., Bhattacharya, A., Takenaka, T., Yoshizumi, T., Long, M. D., & Kufe, D. W. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.20.733526
Kaya, D. M., Ma, Y., Demir, T., Altomare, N., Kalyan, A., Kircher, S. M., Mulcahy, M. F., Benson, A. B., Chen, R., & Mahalingam, D. (2026) · Cancers · doi:10.3390/cancers18132037
Güngörmez, E. K., Şair, O., Aydoğdu, H., Pederiva, F., Yildiz, A. P. Z., Asir, F., & Azizoğlu, M. (2026) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2026.163278
Gesamtüberleben verlängert – aber um wie lang?
Borchers, M., & Klein, F. (2026) · Gastro-News · doi:10.1007/s15036-026-4067-2
Hsiao, Y.-C., Bai, L., Chen, Y.-J., Wu, Y., Wang, W., Chuang, Y.-L., Chang, H., Zeshan, M., Wu, H., Yang, H.-J., et al. (2026) · medRxiv · doi:10.64898/2026.07.01.26356985
Abdelsamia, M., Li, Y., Eastwood, D., & Rabinowitz, I. (2026) · Future Oncology · doi:10.1080/14796694.2026.2699426
A ciência e novas perspectivas no tratamento de pessoas com câncer
Teles, A. L. B. (2025) · Revista Científica Eletrônica do Conselho Regional de Farmácia da Bahia · doi:10.70673/rcecrfba.v5i2.120
Keeping Up to Date in a New Era of Oncology
Beth Faiman, P. (2026) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2026.17.4.1
The Progress of Pancreatectomy for Pancreatic Cancer Treatment—Lessons Learned and Future Challenges
Függer, R., & Biebl, M. (2026) · Cancers · doi:10.3390/cancers18142297
Pictures at an Oncology Exhibition
Peppercorn, J. M. (2026) · JCO Oncology Practice · doi:10.1200/op-26-00720
Kuo, T., Hsiao, K.-C., Liu, K., Chen, L., & Hung, W.-C. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04498-6
OncoFlash - Research Updates in a Flash! (Sep 2026)
Bleaney, C. W., & Jayaprakash, K. T. (2026) · Clinical Oncology · doi:10.1016/j.clon.2026.104308
Guzauskas, G. F., Picozzi, V. J., Guzman, J. F. N. D. R., & Wang, B. C. M. (2026) · Journal of Medical Economics · doi:10.1080/13696998.2026.2707046
Wichtige Studien vom ASCO 2026
Wormann, B. J. (2026) · best practice onkologie · doi:10.1007/s11654-026-00751-7
Balancing cancer innovation with sustainable care
Aggarwal, A. K., & Sullivan, R. J. (2026) · BMJ · doi:10.1136/bmj-2026-250626
Hildebrand, J. S., Capasso, A., Payne, R., Gerrick, K. Y., Hindoyan, A. A., Zhang, A., Clouser, M. C., Eggert, T., Huang, X., & Wainberg, Z. A. (2026) · BMC Cancer · doi:10.21203/rs.3.rs-10359117/v1
Self-citationLiquid Biopsy in Biliary Tract Cancer: When Tissue Is Not Enough
Au, L., & Tie, J. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-26-2090
Mahmasani, L. A., Mourad, M., Abbas, N., & Shamseddine, A. I. (2026) · Current Oncology Reports · doi:10.1007/s11912-026-01812-4
Daraxonrasib and Beyond: Pan‐ RAS Inhibition, Resistance, and Next‐Generation Strategies
Honda, R. P. (2026) · Cancer Science · doi:10.1111/cas.70497
Luo, J., Lee, Y., Cataisson, C., Zhang, H., Gaikwad, S. M., Dubois, W., Michalowski, A. A., Yang, H. H., Meyer, T. J., Young, R., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10581102/v1
Self-citationDaraxonrasib in pancreatic cancer: When progress disrupts practice
Azmi, A. S., & Philip, P. A. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104761
Engineered caspases directly rewire mutant Ras to cell deathPreprint
Moeller, L., Lu, A. C., Ho, K., Zhang, E., & Elowitz, M. B. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.06.743376
From RAS inhibitor resistance to rational combination strategies
Lynch, P., Macarulla, T. M., & O'Kane, G. M. (2026) · Nature Medicine · doi:10.1038/s41591-026-04529-w
Nagata, K., Kajiura, S., Sakumura, M., Nakayama, Y., Ueda, Y., Motoo, I., Ando, T., Ogino, B., Kawanaka, H., Sakamoto, J., et al. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01565-0
Wandmacher, A. M., Bräuer, A., Kayser, C., Stach, C., Werner, J., Beckinger, S., Daunke, T., Baumann, L., Heckelmann, B., Hidam, A. K., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.10.743835
Hackett, D., Kane, L. E., Prina‐Mello, A., & Maher, S. G. (2026) · BMC Medicine · doi:10.1186/s12916-026-05134-x
Daraxonrasib in refractory PDAC: A one-eyed king in the land of the blind?
Orsi, G., & Reni, M. (2026) · Med · doi:10.1016/j.medj.2026.101227
Colloca, G. A., & Venturino, A. (2026) · Journal of Chemotherapy · doi:10.1080/1120009x.2026.2717469
Chien, Y.-T., Huang, J., Zhao, Y., Zhou, Y., Zhang, M., & Mu, Q. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167285
González, J., Cai, X., Diao, W., Roué, G., València-Clua, K., Olmo-González, D., González-Cao, M., Jain, A., Lewintre, E. J., Giménez-Capitán, A. A., et al. (2026) · Neoplasia · doi:10.1016/j.neo.2026.101351
Martín, A. J. M., Zatarain‐Nicolás, E., & Ramírez, S. P. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.107125
Daraxonrasib doubles survival in patients with metastatic pancreatic cancer
Lawrence, L. (2026) · Cancer · doi:10.1002/cncr.70513
Jeon, E., Song, J., & Sim, T. (2026) · Future Medicinal Chemistry · doi:10.1080/17568919.2026.2719780
The KRAS G12C Inhibitor Divarasib Stabilizes RBM39 and Antagonizes Aryl-Sulfonamide DegradersPreprint
Chen, S.-Y., Zou, Y., Wu, J., Nam, G., Lee, H., Chen, Y., Federico, C., Setayeshpour, Y., Lin, C., Wu, S.-C., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.16.745134
Building better binders: De novo generation of TCR-like antibodies specific to oncogenic KRAS
Tsai, A. K., & Stromnes, I. M. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.08.019
Ramachandran, V., Koyou, H. L., Raajasekar, S., Mohamed, M. H., Mat, L. N. I., Swaminathan, V., Salleh, M. N., Prastiyanto, M. E., & Ahmad, N. A. B. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1933939
Adjuvant Therapy in Pancreatic Ductal Adenocarcinoma—Past, Present, and Future
Tran, A., Jain, T., Fei, N. H., & Dudeja, V. (2026) · Cancers · doi:10.3390/cancers18172754
Meng, D., & Zhang, C. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1948028
Lieu, C. (2026) · The Conversation · doi:10.64628/aai.cfaun44f6
The Best Patients for Effective Radiation of Pancreatic Cancer
Fong, Y., & Melstrom, L. G. (2026) · JAMA Surgery · doi:10.1001/jamasurg.2026.3702
Pancreatic cancer: US approves “breakthrough” drug that may double survival time
Iacobucci, G. (2026) · BMJ · doi:10.1136/bmj-2026-100698
RASolute 302: lessons learned and the road ahead in pancreatic cancer
Ko, A. H. (2026) · The Oncologist · doi:10.1093/oncolo/oyag346
The long return on discovery science in cancer therapeutics
Murphy, C., Hume, S., & Swanton, C. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00978-0
Equipoise lost in pancreatic cancer: reimagining crossover for promising cancer therapies
Vora, K. B., & Bates, S. E. (2026) · The Oncologist · doi:10.1093/oncolo/oyag347
Progress and challenges in expanding access to clinical trials in pancreatic cancer
Thang, S. S., Croagh, D., Ananda, S. S., Metz, A. J., Cooray, P. D., & Poh, A. R. (2026) · Communications Medicine · doi:10.1038/s43856-026-01869-z
Metadata
- Authors
- O’Reilly, E. M., Wainberg, Z. A., Hendifar, A. E., Borad, M. J., Pietrantonio, F., Pant, S., Hammel, P., Cremolini, C., Manji, G. A., Oberstein, P. E., Garrido-Laguna, I., Springfeld, C., Azad, N. S., Ueno, M., Chui, S. Y., Zhang, Y., Patel, H., Lee, Y., Salman, Z., & Wolpin, B. M.
- Affiliations
- Memorial Sloan Kettering Cancer Center, New York
- University of California, Los Angeles (US)
- Cedars-Sinai Medical Center (US)
- Mayo Clinic in Arizona (US)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- The University of Texas MD Anderson Cancer Center (US)
- Université Paris-Saclay (FR)
- University of Pisa (IT)
- Columbia University Irving Medical Center (US)
- NYU Langone Health (US)
- Huntsman Cancer Institute, University of Utah, Salt Lake City
- University Hospital Heidelberg (DE)
- Sidney Kimmel Comprehensive Cancer Center (US)
- Kanagawa Cancer Center (JP)
- Revolution Medicines (United States) (US)
- Dana-Farber Cancer Institute (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2026-07-23
- Volume
- 395
- Issue
- 4
- Pages
- 325-337
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W7162952636
- Cited by
- 147
- References
- 30
- Citations by year
- 2026: 147
- FWCI
- 431.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Revolution Medicines
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- daraxonrasib, metastatic pancreatic ductal adenocarcinoma, RAS inhibitors, previously treated patients, chemotherapy comparison, overall survival, progression-free survival, adverse events, treatment discontinuation
- MeSH terms
- Gain of Function Mutation, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Middle Aged, Pancreatic Neoplasms, Piperazines, Quality of Life, Time Factors, ras Proteins, Carcinoma, Pancreatic Ductal, Kaplan-Meier Estimate, Response Evaluation Criteria in Solid Tumors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.